Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COVIVAC Vaccine Phase 1/2 in Vietnam
NCT05940194Phase 2Completed
- Sponsor
- Institute of Vaccines and Medical Biologicals
- Start
- Aug 2021
- Primary completion
- Oct 2021
- Modality
- Live Attenuated Vaccines
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of COVI-VAC in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Institute of Vaccines and Medical Biologicals. Primary endpoints: Percentage of Participants With Local and Systemic Solicited Adverse Events, Percentage of Participants With Unsolicited Adverse Events and 4 more. Started Aug 2021; status: completed.
02
Drugs
COVI-VAC
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05940194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05940194.